Array And Oncothyreon Team Up On Oral HER2 Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncothyreon agreed to pay $10 million upfront for rights to Array’s oral HER2 inhibitor in development for breast cancer. Under the arrangement, Oncothyreon will fund and conduct proof-of-concept studies, but both companies will be responsible for Phase III development and potentially commercialization.